← Find more feeds

takeda.com

Takeda Pharmaceutical Company Limited

Get the latest updates from Takeda Pharmaceutical Company Limited directly as they happen.

Follow now 45 followers

Latest posts

Last updated about 2 years ago

Takeda to Present Multiple New Data Analyses at 2023 AAAAI Annual Meeting, Including SPRING Study of TAKHZYRO® (lanadelumab-flyo) in Pediatric Patients With Hereditary Angioedema (HAE)

about 2 years ago

Read full

Takeda Completes Acquisition of Nimbus Therapeutics’ TYK2 Program Subsidiary

about 2 years ago

Read full

U.S. FDA Approves Takeda’s TAKHZYRO® (lanadelumab-flyo) to Prevent Hereditary Angioedema (HAE) Attacks in Children 2 Years of Age and Older

over 2 years ago

Read full

Takeda Reinforces Long-term Growth Through Pipeline Advancement and Two Targeted Acquisitions Delivers Another Strong Quarter in FY2022 Q3

over 2 years ago

Read full

Takeda to Hold Third Quarter FY2022 Earnings Call on February 2

over 2 years ago

Read full

Takeda To Acquire Exclusive Worldwide (ex-China) License of HUTCHMED’s Fruquintinib, a Highly Selective, Oral VEGFR1/2/3 Tyrosine Kinase Inhibitor

over 2 years ago

Read full

Takeda Named Global Top Employer for Sixth Consecutive Year

over 2 years ago

Read full

Takeda’s EXKIVITY® (mobocertinib) Receives Approval from the NMPA of China, Becoming the First and Only Therapy Available for Patients with EGFR Exon20 Insertion+ NSCLC

over 2 years ago

Read full

Arrowhead and Takeda Announce Topline Results from SEQUOIA Phase 2 Study of Fazirsiran in Patients with Alpha-1 Antitrypsin Deficiency-Associated Liver Disease

over 2 years ago

Read full

Takeda Announces Favorable Phase 3 Safety and Efficacy Results of TAK-755 as Compared to Standard of Care in Congenital Thrombotic Thrombocytopenic Purpura (cTTP)

over 2 years ago

Read full

Takeda CEO Christophe Weber to Present at J.P. Morgan Healthcare Conference

over 2 years ago

Read full

Takeda’s Phase 3 AURORA Study Provides Evidence of Maribavir’s Clinically Meaningful and Durable Effect in Cytomegalovirus (CMV) Infection in Hematopoietic Stem Cell Transplant Patients, Despite Missing Primary Endpoint

over 2 years ago

Read full

Or log in

Everything you care about in one place

Takeda Pharmaceutical Company Limited

Latest posts

Takeda to Present Multiple New Data Analyses at 2023 AAAAI Annual Meeting, Including SPRING Study of TAKHZYRO® (lanadelumab-flyo) in Pediatric Patients With Hereditary Angioedema (HAE)

Takeda Completes Acquisition of Nimbus Therapeutics’ TYK2 Program Subsidiary

U.S. FDA Approves Takeda’s TAKHZYRO® (lanadelumab-flyo) to Prevent Hereditary Angioedema (HAE) Attacks in Children 2 Years of Age and Older

Takeda Reinforces Long-term Growth Through Pipeline Advancement and Two Targeted Acquisitions Delivers Another Strong Quarter in FY2022 Q3

Takeda to Hold Third Quarter FY2022 Earnings Call on February 2

Takeda To Acquire Exclusive Worldwide (ex-China) License of HUTCHMED’s Fruquintinib, a Highly Selective, Oral VEGFR1/2/3 Tyrosine Kinase Inhibitor

Takeda Named Global Top Employer for Sixth Consecutive Year

Takeda’s EXKIVITY® (mobocertinib) Receives Approval from the NMPA of China, Becoming the First and Only Therapy Available for Patients with EGFR Exon20 Insertion+ NSCLC

Arrowhead and Takeda Announce Topline Results from SEQUOIA Phase 2 Study of Fazirsiran in Patients with Alpha-1 Antitrypsin Deficiency-Associated Liver Disease

Takeda Announces Favorable Phase 3 Safety and Efficacy Results of TAK-755 as Compared to Standard of Care in Congenital Thrombotic Thrombocytopenic Purpura (cTTP)

Takeda CEO Christophe Weber to Present at J.P. Morgan Healthcare Conference

Takeda’s Phase 3 AURORA Study Provides Evidence of Maribavir’s Clinically Meaningful and Durable Effect in Cytomegalovirus (CMV) Infection in Hematopoietic Stem Cell Transplant Patients, Despite Missing Primary Endpoint

Try Feeder for free